This inventor holds 34 USPTO granted patents and 22 published patent applications, plus 1 CIPO patent and 12 EPO patents, primarily in Viral Vaccines. Top assignees: Seqirus UK Limited, Novartis Ag, Glaxosmithkline Biologicals Sa. Active years: 2013-2025.
Location History:
- Emeryville, CA (US) (2019)
- Cambridge, MA (US) (2014 - 2020)
- Armonk, NY (US) (2018 - 2021)
- Weston, MA (US) (2013 - 2023)
- Nyack, NY (US) (2023 - 2024)
Company Filing History:
10 out of 37 
8 out of 3,974 
7 out of 545 
Years Active: 2013-2025
Areas of Expertise:
Title: Philip R. Dormitzer: Pioneering Innovations in Immunology
Introduction
Philip R. Dormitzer, based in Weston, MA, is an accomplished inventor with a notable portfolio of 32 patents. His work primarily focuses on innovations in the field of immunology, particularly relating to viral proteins and their applications in vaccine development.
Latest Patents
Dormitzer's recent patents include significant advancements such as the invention concerning the human cytomegalovirus (CMV) glycoprotein B (gB) protein. This invention encompasses mutants of the wild-type CMV glycoprotein B, featuring at least two amino acid mutations. The invention aims to create stabilized mutants that present alternative conformations, enhancing their usability in therapeutic applications.
Another notable patent involves respiratory syncytial virus (RSV) F protein compositions. This invention relates to immunogenic compositions comprising RSV F protein and details methods for preparing ecto-domain polypeptides of the RSV F protein. The compositions are engineered to evoke an immune response and represent key advancements in combating viral infections.
Career Highlights
Throughout his career, Dormitzer has worked for prominent companies, including Seqirus UK Limited and Novartis AG. His contributions have significantly shaped the landscape of vaccine research and development, marking him as a leader in the biotechnology industry.
Collaborations
In his professional journey, Dormitzer has collaborated with esteemed colleagues such as Peter W. Mason and Pirada Suphaphiphat. These collaborations have fostered innovative approaches in addressing critical health challenges, particularly in designing effective immunological responses.
Conclusion
Philip R. Dormitzer exemplifies the spirit of innovation in the field of immunology. With his extensive patent portfolio and collaborative efforts, he continues to make impactful contributions that advance health science and technology. His work lays the groundwork for future developments in vaccine research and provides insights into combatting viral diseases.